CDK4&6 Inhibition

Differences Between CDK4&6 Inhibitors Predict Future Approaches

May 28, 2016

Clinical Articles

Cyclin-dependent kinase 4 (CDK4) and CDK6 inhibitors are a promising class of anticancer agents that may present effective alternatives to standard therapy for women with advanced, refractory, or relapsed hormone receptor (HR)‒positive breast cancer.